A Win For Hoth Therapeutics, Inc.
Thu, Dec 15, 2022 at 06:58 PM
Hoth Therapeutics, Inc. (HOTH:NASDAQ) soared at $4.17, a gain of 31.1%. On Thu, Dec 15, 2022, HOTH:NASDAQ hit a New 2-Week High of $4.17. The stock appeared on our News Catalysts scanner on Thu, Dec 01, 2022 at 11:32 AM in the 'INVESTOR UPDATE' category. From Thu, Dec 01, 2022, the stock recorded 30.00% Up Days and 9.09% Green Days
About Hoth Therapeutics, Inc. (HOTH:NASDAQ)
Hoth Therapeutics Inc is a development stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Top 10 Gainers:
- Larkspur Health Acquisition Corp. (LSPR:NASDAQ), 132.68%
- Core Scientific Inc Cl A (CORZ:NASDAQ), 72%
- IMV Inc. (IMV:NASDAQ), 66.55%
- Creatd Inc. (CRTD:NASDAQ), 57.76%
- Scopus BioPharma Inc. (SCPS:NASDAQ), 44.85%
- BeyondSpring Inc. (BYSI:NASDAQ), 33.04%
- Hoth Therapeutics, Inc. (HOTH:NASDAQ), 31.13%
- Nuvve Holding Corp. (NVVE:NASDAQ), 31.05%
- Landos Biopharma Inc. (LABP:NASDAQ), 30.46%
- NewAmsterdam Pharma Company N.V. (NAMS:NASDAQ), 27.66%